Fairvoy Private Wealth LLC Purchases Shares of 2,255 Encompass Health Co. (NYSE:EHC)

Fairvoy Private Wealth LLC acquired a new position in Encompass Health Co. (NYSE:EHC) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 2,255 shares of the company’s stock, valued at approximately $208,000.

Several other hedge funds have also recently added to or reduced their stakes in EHC. MassMutual Private Wealth & Trust FSB raised its stake in Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after purchasing an additional 137 shares during the last quarter. UMB Bank n.a. lifted its stake in Encompass Health by 387.7% during the third quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after purchasing an additional 252 shares during the period. V Square Quantitative Management LLC grew its stake in shares of Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after purchasing an additional 140 shares during the period. Avior Wealth Management LLC acquired a new position in Encompass Health during the third quarter worth $40,000. Finally, Tompkins Financial Corp acquired a new stake in shares of Encompass Health in the 4th quarter valued at $46,000. Institutional investors own 97.25% of the company’s stock.

Encompass Health Price Performance

Encompass Health stock opened at $99.86 on Friday. The stock has a market cap of $10.06 billion, a price-to-earnings ratio of 24.12, a P/E/G ratio of 1.18 and a beta of 0.90. Encompass Health Co. has a 12-month low of $72.37 and a 12-month high of $104.55. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The business’s 50-day simple moving average is $96.28 and its 200 day simple moving average is $95.19.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. As a group, research analysts anticipate that Encompass Health Co. will post 4.29 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on EHC. Barclays lifted their price target on shares of Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a report on Friday. Royal Bank of Canada increased their price target on Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. StockNews.com downgraded Encompass Health from a “buy” rating to a “hold” rating in a research report on Friday. William Blair restated an “outperform” rating on shares of Encompass Health in a report on Friday. Finally, Truist Financial reaffirmed a “buy” rating and issued a $116.00 price target (up from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $107.33.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.